GEN-PROBE INCORPORATED

Gen-Probe Incorporated specializes in the manufacturing and supply of in-vitro diagnostic substances, with deep expertise in molecular assay systems for infectious disease detection. The company delivers proprietary reagents and consumables for nucleic acid amplification technologies, including high-throughput platforms such as the Hologic Panther Fusion system. Their technical capabilities center on assay development for pathogens like HIV-1, HPV, Chlamydia trachomatis, Neisseria gonorrhoeae, and Mycobacterium tuberculosis, supporting clinical and military diagnostic workflows with FDA-cleared and CE-marked products. Key differentiators include robust assay specificity, automation compatibility, and supply chain reliability for mission-critical testing environments. The contractor maintains a strong, sustained relationship with the Department of Defense, providing diagnostic kits and service agreements essential to force health protection and readiness programs. These engagements include rapid-response reagent supply for emerging threats such as COVID-19 and routine screening for sexually transmitted infections in deployed settings. Additional work with the Department of Veterans Affairs and the Department of Health and Human Services underscores their role in public health surveillance and compliance-driven testing initiatives, particularly under regulatory mandates like EO14042. Primarily operating under NAICS 325413, Gen-Probe focuses on the production of clinical diagnostic reagents and assay kits, positioning itself as a niche supplier in the molecular diagnostics space for government health and defense applications. Their limited engagement in surgical supplies and support services reflects a strategic concentration on diagnostic substance manufacturing rather than broad medical device distribution. Based in Marlborough, Massachusetts, Gen-Probe operates as a privately held entity (2L structure) without federal certifications. Their geographic footprint is centered on the U.S. biotech corridor, enabling close collaboration with federal laboratories and procurement channels. The company’s market positioning is defined by technical precision in diagnostic reagent development and consistent delivery to high-reliability government users.